S&P 500   4,172.59 (-0.78%)
DOW   32,765.88 (-0.84%)
QQQ   347.56 (-0.69%)
AAPL   177.74 (+0.25%)
MSFT   330.98 (-0.07%)
META   262.73 (+0.08%)
GOOGL   123.21 (-0.37%)
AMZN   120.12 (-1.27%)
TSLA   197.32 (-1.91%)
NVDA   391.87 (-2.30%)
NIO   7.27 (-1.89%)
BABA   78.36 (-0.39%)
AMD   121.16 (-3.28%)
T   15.76 (+0.77%)
F   12.13 (-3.65%)
MU   68.17 (-4.91%)
CGC   0.81 (-4.73%)
GE   100.78 (-1.58%)
DIS   87.43 (-0.44%)
AMC   4.51 (-2.59%)
PFE   37.33 (+0.86%)
PYPL   61.94 (-0.18%)
NFLX   392.11 (-0.22%)
S&P 500   4,172.59 (-0.78%)
DOW   32,765.88 (-0.84%)
QQQ   347.56 (-0.69%)
AAPL   177.74 (+0.25%)
MSFT   330.98 (-0.07%)
META   262.73 (+0.08%)
GOOGL   123.21 (-0.37%)
AMZN   120.12 (-1.27%)
TSLA   197.32 (-1.91%)
NVDA   391.87 (-2.30%)
NIO   7.27 (-1.89%)
BABA   78.36 (-0.39%)
AMD   121.16 (-3.28%)
T   15.76 (+0.77%)
F   12.13 (-3.65%)
MU   68.17 (-4.91%)
CGC   0.81 (-4.73%)
GE   100.78 (-1.58%)
DIS   87.43 (-0.44%)
AMC   4.51 (-2.59%)
PFE   37.33 (+0.86%)
PYPL   61.94 (-0.18%)
NFLX   392.11 (-0.22%)
S&P 500   4,172.59 (-0.78%)
DOW   32,765.88 (-0.84%)
QQQ   347.56 (-0.69%)
AAPL   177.74 (+0.25%)
MSFT   330.98 (-0.07%)
META   262.73 (+0.08%)
GOOGL   123.21 (-0.37%)
AMZN   120.12 (-1.27%)
TSLA   197.32 (-1.91%)
NVDA   391.87 (-2.30%)
NIO   7.27 (-1.89%)
BABA   78.36 (-0.39%)
AMD   121.16 (-3.28%)
T   15.76 (+0.77%)
F   12.13 (-3.65%)
MU   68.17 (-4.91%)
CGC   0.81 (-4.73%)
GE   100.78 (-1.58%)
DIS   87.43 (-0.44%)
AMC   4.51 (-2.59%)
PFE   37.33 (+0.86%)
PYPL   61.94 (-0.18%)
NFLX   392.11 (-0.22%)
S&P 500   4,172.59 (-0.78%)
DOW   32,765.88 (-0.84%)
QQQ   347.56 (-0.69%)
AAPL   177.74 (+0.25%)
MSFT   330.98 (-0.07%)
META   262.73 (+0.08%)
GOOGL   123.21 (-0.37%)
AMZN   120.12 (-1.27%)
TSLA   197.32 (-1.91%)
NVDA   391.87 (-2.30%)
NIO   7.27 (-1.89%)
BABA   78.36 (-0.39%)
AMD   121.16 (-3.28%)
T   15.76 (+0.77%)
F   12.13 (-3.65%)
MU   68.17 (-4.91%)
CGC   0.81 (-4.73%)
GE   100.78 (-1.58%)
DIS   87.43 (-0.44%)
AMC   4.51 (-2.59%)
PFE   37.33 (+0.86%)
PYPL   61.94 (-0.18%)
NFLX   392.11 (-0.22%)
NASDAQ:RVNC

Revance Therapeutics (RVNC) Stock Forecast, Price & News

$30.01
-0.26 (-0.86%)
(As of 10:39 AM ET)
Compare
Today's Range
$29.91
$30.84
50-Day Range
$30.00
$37.61
52-Week Range
$11.27
$37.98
Volume
116,544 shs
Average Volume
1.47 million shs
Market Capitalization
$2.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.36

Revance Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
40.0% Upside
$42.36 Price Target
Short Interest
Bearish
17.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
1.46mentions of Revance Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$8.28 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.78) to ($1.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

501st out of 1,009 stocks

Pharmaceutical Preparations Industry

240th out of 494 stocks


RVNC stock logo

About Revance Therapeutics (NASDAQ:RVNC) Stock

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Stock News Headlines

Revance Therapeutics (NASDAQ: RVNC)
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Revance Therapeutics (NASDAQ:RVNC) Shares Gap Down to $37.61
Revance Therapeutics (NASDAQ:RVNC) PT Raised to $50.00
See More Headlines
Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Company Calendar

Last Earnings
5/09/2023
Today
5/30/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVNC
Employees
495
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$42.36
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+40.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$-356,420,000.00
Net Margins
-224.65%
Pretax Margin
-224.20%

Debt

Sales & Book Value

Annual Sales
$132.57 million
Book Value
$0.15 per share

Miscellaneous

Free Float
80,976,000
Market Cap
$2.54 billion
Optionable
Optionable
Beta
0.84

Key Executives

  • Mark J. FoleyMark J. Foley
    Chief Executive Officer & Director
  • Dustin S. Sjuts
    President
  • Tobin C. SchilkeTobin C. Schilke
    Chief Financial Officer
  • Azita Nejad
    Senior Vice President-Technical Operations
  • Roman G. Rubio
    Senior Vice President-Clinical Development













RVNC Stock - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVNC shares.
View RVNC analyst ratings
or view top-rated stocks.

What is Revance Therapeutics' stock price forecast for 2023?

8 Wall Street research analysts have issued twelve-month price objectives for Revance Therapeutics' shares. Their RVNC share price forecasts range from $26.00 to $65.00. On average, they predict the company's share price to reach $42.36 in the next year. This suggests a possible upside of 40.0% from the stock's current price.
View analysts price targets for RVNC
or view top-rated stocks among Wall Street analysts.

How have RVNC shares performed in 2023?

Revance Therapeutics' stock was trading at $18.46 at the start of the year. Since then, RVNC shares have increased by 64.0% and is now trading at $30.27.
View the best growth stocks for 2023 here
.

When is Revance Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our RVNC earnings forecast
.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.01. The biopharmaceutical company had revenue of $49.33 million for the quarter, compared to analysts' expectations of $46.21 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 1,091.00% and a negative net margin of 224.65%. The business's quarterly revenue was up 95.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.94) earnings per share.

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Palo Alto Investors LP (6.27%), Thrivent Financial for Lutherans (2.40%), State Street Corp (2.32%), FMR LLC (2.20%), Jennison Associates LLC (1.95%) and Geode Capital Management LLC (1.90%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke.
View institutional ownership trends
.

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $30.27.

How much money does Revance Therapeutics make?

Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $2.54 billion and generates $132.57 million in revenue each year. The biopharmaceutical company earns $-356,420,000.00 in net income (profit) each year or ($4.61) on an earnings per share basis.

How many employees does Revance Therapeutics have?

The company employs 495 workers across the globe.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401.

This page (NASDAQ:RVNC) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -